Optimi Health Establishes Optimi Australia Pty Ltd as Dedicated Distribution and Business Development Entity
6-K
Optimi Health Completes MDMA Production for Phase 3 PTSD Trial in Canada, MAPS Trial in Israel and Commercial Supply in Australia
6-K
Optimi Health to Present at the ThinkEquity Conference
6-K
Optimi Health Appoints Melanie Pump to Board of Directors and Announces Management Changes
6-K
Optimi Health Completes Psilocybin Production for Health Canada-Approved Phase 2 MDD Trial and Commercial TRD Supply
6-K
Optimi Health Appoints Dr. Michael Blough as Chief Clinical Development Officer
Prospectus
TYPE
HEADLINE
FILED AT
Registrations
TYPE
HEADLINE
FILED AT
F-1
Seven Knots, LLC - SPA - 97% of the lower of the purchase day's low and pricing-period VWAP. Up to 30% of daily volume, capped at $2 million per VWAP Purchase. $1.00 prior-close floor; 4.99% ownership cap.
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
8-A12B
Form 8-A12B - Registration of securities [Section 12(b)]
